STAT Plus: Next up for KRAS-blocking cancer drug fans: a hugely important data reveal from Mirati Therapeutics By ADAM FEUERSTEIN

STAT Plus: Next up for KRAS-blocking cancer drug fans: a hugely important data reveal from Mirati Therapeutics

By ADAM FEUERSTEIN

APSTOCK

Investor expectations are running high for Mirati Therapeutics, whose upcoming trial readout may be an important stock-moving catalyst.

READ MORE